A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

This study is testing a new drug called TLN-254 in people with T-cell lymphoma — a rare type of blood cancer — that has come back or stopped responding to prior treatment. The study includes multiple types of T-cell lymphoma. **You may be eligible if...** - You are 18 or older - You have been diagnosed with peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL) that has relapsed or is refractory (not responding) after at least one prior treatment - If you have a specific subtype called anaplastic large cell lymphoma (ALCL), you must have previously received brentuximab vedotin - You have measurable disease on imaging - Your organ function is adequate **You may NOT be eligible if...** - You have active brain involvement by lymphoma - You have uncontrolled serious infections or other active cancers - You have had certain prior treatments that would exclude you based on the protocol - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.